New scan could spot brain tumors more clearly

NCT ID NCT06055790

Recruiting now Diagnosis Sponsor: University of Arizona Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tests a special PET/CT scan using a tracer called 18F-Fluciclovine to see if it can better detect brain metastases and tell them apart from changes caused by earlier treatments. About 20 adults with known or suspected brain metastases will get the scan before and after treatment. The goal is to improve diagnosis and monitoring of brain tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Fluciclovine (Axumin) – a radioactive tracer used in PET/CT scans
What this could lead to: If successful, this scan could help doctors more accurately identify brain metastases and tell them apart from harmless post-treatment changes, improving treatment decisions.
What could go wrong: This is a small early-phase study with only 20 participants, so results may not apply to everyone. The scan is not yet proven to be better than current standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES

Contacts and locations

Locations

Arizona Cancer Center at UMC North/University Medical Center
RECRUITING

Tucson, Arizona, 85719, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.